logo
  

Daqo New Energy Q1 Net Profit Tanks; Stock Down In Pre-market

Daqo New Energy Corp. (DQ), a Chinese maker of monocrystalline silicon and polysilicon for solar photovoltaic systems, on Monday reported a steep decline in net profit for the first-quarter. Earnings were impacted by decreased revenue reflecting a fall in Polysilicon average selling price and higher inventories.

Following the news, DQ was trading down by 3.66 percent at $22.87 in the pre-market trade on the New York Stock Exchange.

For the three-month period, the company reported a net income of $15.5 million, lesser than $278.804 million, registered for the same period last year.

Income per American Depository Share or ADS stood at $0.24, compared with $3.52 per ADS a year ago.

Excluding items, earnings were $36 million, down from $310.205 million in the previous year.

Daqo reported adjusted earnings per ADS of $0.55, compared with $3.93 a year ago.

Income before income taxes plunged to $42.510 million from last year's $475.762 million.

Excluding items, EBITDA stood at 76.9 million, versus previous year's $490.214 million.

Income from operations plunged to $30.5 million from last year's $463.802 million.

Revenues slipped to $415.3 million from $709.834 million in 2023.

Looking ahead, for the full year, Xiang Xu, CEO of Daqo New Energy, said: "We expect Q2 2024 total polysilicon production volume to be approximately 60,000 MT to 63,000 MT, similar to that of Q1 2024 as the Company maintains full production. We expect to finish construction and begin initial pilot production at our new Inner Mongolia Phase 5B facility in Q2 2024 and expect to ramp up to full production level by the end of Q3 2024. As a result, we anticipate full year 2024 production volume to be in the range of 280,000 MT to 300,000 MT, approximately 40% to 50% higher than that of 2023."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AbbVie (ABBV) Monday announced a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage neuroscience biotech firm, to develop next-generation treatment approaches and unmet needs in psychiatric disorders. AbbVie noted that the first-generation compounds may... Healthwest Minerals, Inc. d/b/a Mt. Capra Products has recalled 1,506 boxes of Goat Milk Formula Recipe Kit, also urging consumers to immediately discontinue use of the product as infant formula. The firm does not recommend using this product for infants from 0-12 months of age. Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Follow RTT